Skip to main content

Tracon Pharmaceuticals, Inc.

TCONDelisted Jul 19, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001394319

Tracon Pharmaceuticals, Inc. was delisted on Jul 19, 2024; its insiders filed their last Form 4 on Mar 13, 2024; 29 institutions reported holding it in 13F filings for Q1 2024, worth $1.39M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tracon Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tracon Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tracon Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Brown Scott B.CHIEF FINANCIAL OFFICER25,128Mar 13, 20240
Theuer CharlesPRESIDENT AND CEO406,417Mar 13, 20240
Opaleye Management Inc.10% Owner0IndirectNov 14, 20230
Pelletier Saundra LDirector12,045Apr 21, 20230
Mattingly Martin ADirector–Apr 21, 20230
Larue William RDirector7,763Apr 21, 20230
Worland Stephen TDirector–Apr 21, 20230
Twiford J RainerDirector–Apr 21, 20230
Lam Carol C.Director–Apr 21, 20230
Johnson-Pratt LisaDirector–Apr 21, 20230
Adams Bonne J.Chief Operating Officer–Feb 9, 20230
Wiggins Mark CChief Business Officer–Feb 1, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 15, 2022 (view filing)Dec 141 dayTheuer CharlesPresident and CEOPPurchase+23.0K$1.29+$29.7K+7.4%333.1K after
Dec 16, 2022 (view filing)Dec 142 daysOpaleye Management Inc.10% OwnerPPurchaseCommon Stock, par value $0.001 per share+167.5K$1.26+$210.5K+61.5%440.0K after2 lots
Jan 3, 2023 (view filing)Dec 29, 20225 daysBrown Scott B.Chief Financial OfficerPPurchase+3.50K$1.49+$5.21K+19.3%21.6K after
Jan 19, 2023 (view filing)Dec 21, 202229 daysLateLarue William RDirectorSSale−120$1.26−$151.2−1.5%7.76K after
Jan 19, 2023 (view filing)Jan 181 dayTheuer CharlesPresident and CEOPPurchase+6.80K$1.62+$11.0K+2.0%339.9K after
Mar 2, 2023 (view filing)Feb 28-Mar 12 daysTheuer CharlesPresident and CEOPPurchase+5.00K$1.52+$7.60K+1.5%344.9K after2 lots
Mar 13, 2023 (view filing)Mar 94 daysOpaleye Management Inc.10% OwnerPPurchaseCommon Stock, par value $0.001 per share+174.5K$1.38+$240.8K+4.2%4.32M after
Apr 28, 2023 (view filing)Apr 26-272 daysTheuer CharlesPresident and CEOPPurchase+51.0K$0.7429+$37.9K+14.6%399.4K after2 lots
Nov 14, 2023 (view filing)4:05 PM ETNov 104 daysOpaleye Management Inc.10% OwnerSSaleCommon Stock, par value $0.001 per share−4.76M$0.2942−$1.40M−100.0%0 after2 lots